Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
LQDA Stock Chart & Stats
$42.40
<$0.01(<0.01%)
At close: 4:00 PM EST
$42.40
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$11.26 - $46.67
Previous CloseN/A
Volume97.81K
Average Volume (3M)1.96M
Market Cap
$3.69B
Enterprise Value$3.73B
Total Cash (Recent Filing)$157.50M
Total Debt (Recent Filing)$199.18M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Mar 12, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding86,995,480
10 Day Avg. Volume1,764,686
30 Day Avg. Volume1,962,005
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)11.98
Price to Sales (P/S)66.13
P/FCF Ratio-9.41
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue53.89
Enterprise Value/Gross Profit60.28
Enterprise Value/Ebitda-37.88
Forecast
1Y Price Target
$46.75Price Target Upside10.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial PerformanceAnalyst highlights that Yutrepia's strong early patient adoption, improved prescription-to-start conversion, and achieved profitability indicate sustained commercial momentum and robust demand.
Market Access And Salesforce ExpansionManagement's expansion of the salesforce combined with contracts with major commercial payors is positioned to broaden physician coverage and improve patient access, supporting further uptake.
Pipeline DevelopmentAnalyst notes that the next-generation therapy L606 and planned randomized and open-label studies could extend the company's revenue runway by adding clinically differentiated options for important patient groups.
Bears Say
Clinical Data Timing UncertaintyAnalyst warns that unclear timing of planned study readouts increases uncertainty about when clinical results will generate meaningful catalysts, reducing near-term visibility for investors.
Patent Litigation RiskPending litigation over the '327 patent creates a legal overhang that could disrupt sales continuity, lead to restrictive labeling outcomes, or otherwise impair commercial growth.
Sales Visibility VariabilityAnalyst cautions that seasonal and specialty-pharmacy ordering patterns can create variability in patient starts and prescription flows, producing volatility in short-term sales visibility.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $11.26 and its highest was $46.67 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $3.69B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Mar 12, 2026 which is in 28 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Nov 03, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.389 by $0.349.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is 0.19.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 86,995,480 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.389. Following the earnings report the stock price went up 3.53%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.75 (10.26% Upside)
$46.75 (10.26% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
169.20%
12-Months-Change
Fundamentals
Return on Equity
-183.82%
Trailing 12-Months
Asset Growth
9.13%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Liquidia has experienced a strong launch and financial performance with YUTREPIA, achieving significant prescription uptake and positive cash flow. However, the ongoing net loss and litigation uncertainty present challenges that could impact future performance.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$46.75
▲(10.26% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
22.66% Insiders
7.35% Mutual Funds
0.21% Other Institutional Investors
60.24% Public Companies and Individual Investors